[go: up one dir, main page]

PE20121171A1 - METHOD, KIT, PLASMID AND COMPOSITION TO INDUCE AN IMMUNE RESPONSE AGAINST DENGUE VIRUS BASED ON DNA VACCINES AND CHEMERIC VIRUSES - Google Patents

METHOD, KIT, PLASMID AND COMPOSITION TO INDUCE AN IMMUNE RESPONSE AGAINST DENGUE VIRUS BASED ON DNA VACCINES AND CHEMERIC VIRUSES

Info

Publication number
PE20121171A1
PE20121171A1 PE2012000411A PE2012000411A PE20121171A1 PE 20121171 A1 PE20121171 A1 PE 20121171A1 PE 2012000411 A PE2012000411 A PE 2012000411A PE 2012000411 A PE2012000411 A PE 2012000411A PE 20121171 A1 PE20121171 A1 PE 20121171A1
Authority
PE
Peru
Prior art keywords
dengue virus
viruses
composition
dna vaccines
chemeric
Prior art date
Application number
PE2012000411A
Other languages
Spanish (es)
Inventor
Ada Maria De Barcelos Alves
Adriana De Souza Azevedo
Ricardo Galler
Marcos Da Silva Freire
Original Assignee
Fundação Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43825448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121171(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundação Oswaldo Cruz filed Critical Fundação Oswaldo Cruz
Publication of PE20121171A1 publication Critical patent/PE20121171A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UNA COMPOSICION DE VACUNA CONTRA EL VIRUS DEL DENGUE QUE COMPRENDE: a) VACUNAS DE ADN CONTRA LOS CUATRO SEROTIPOS DEL VIRUS DEL DENGUE A PARTIR DE LA CONSTRUCCION DE DIFERENTES PLASMIDOS RECOMBINANTES QUE CONTIENEN LOS GENES QUE CODIFICAN PARA LAS PROTEINAS E DE CADA SEROTIPO DEL VIRUS DEL DENGUE, O SOLO LAS SECUENCIAS CORRESPONDIENTES A LOS DOMINIOS III DE ESTAS PROTEINAS, TODAS FUSIONADAS A LA SECUENCIA QUE CODIFICA PARA EL PEPTIDO SENAL DEL ACTIVADOR DEL PLASMINOGENO TISULAR HUMANO (t-PA), b) VIRUS QUIMERICOS QUE COMPRENDEN EL VIRUS DE LA VACUNA DE LA FIEBRE AMARILLA 17D MODIFICADO, CON LA SUSTITUCION DE LAS SECUENCIAS QUE CODIFICAN PARA LAS PROTEINAS prM Y E DE LA FEBRE AMARILLA POR SECUENCIAS QUE CODIFICAN PARA LAS PROTEINAS prM Y E DEL VIRUS DEL DENGUE DE DIFERENTES SEROTIPOS Y c) UN VEHICULO FARMACEUTICAMENTE ACEPTABLEREFERRING TO A COMPOSITION OF VACCINE AGAINST DENGUE VIRUS THAT INCLUDES: a) DNA VACCINES AGAINST THE FOUR SEROTYPES OF DENGUE VIRUS FROM THE CONSTRUCTION OF DIFFERENT RECOMBINANT PLASMIDES THAT CONTAIN THE GENES OF THE CODIFYING PROTEINES DENGUE VIRUSES, OR ONLY THE SEQUENCES CORRESPONDING TO THE DOMAINS III OF THESE PROTEINS, ALL FUSED TO THE SEQUENCE THAT CODES FOR THE SIGNAL PEPTIDE OF THE ACTIVATOR OF THE HUMAN TISULAR PLASMINOGEN (t-PA), b) COMMON VIRUSES OF CHEMICALS MODIFIED 17D YELLOW FEVER VACCINE, WITH THE SUBSTITUTION OF THE SEQUENCES THAT CODE FOR THE PROTEINS prM YE OF THE YELLOW FEBRUARY BY SEQUENCES THAT CODE FOR THE PROTEINS OF THE DENGUE VIRUS OF DIFFERENT PHARMACY DIFFERENT ACCESSIBLE (C)

PE2012000411A 2009-10-01 2010-08-01 METHOD, KIT, PLASMID AND COMPOSITION TO INDUCE AN IMMUNE RESPONSE AGAINST DENGUE VIRUS BASED ON DNA VACCINES AND CHEMERIC VIRUSES PE20121171A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0904020A BRPI0904020B8 (en) 2009-10-01 2009-10-01 vaccine composition against the dengue virus, and kit

Publications (1)

Publication Number Publication Date
PE20121171A1 true PE20121171A1 (en) 2012-08-30

Family

ID=43825448

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000411A PE20121171A1 (en) 2009-10-01 2010-08-01 METHOD, KIT, PLASMID AND COMPOSITION TO INDUCE AN IMMUNE RESPONSE AGAINST DENGUE VIRUS BASED ON DNA VACCINES AND CHEMERIC VIRUSES
PE2016001214A PE20161094A1 (en) 2009-10-01 2010-08-01 METHOD, KIT, PLASMID AND COMPOSITION TO INDUCE AN IMMUNE RESPONSE AGAINST DENGUE VIRUS BASED ON DNA VACCINES AND CHEMERIC VIRUSES

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016001214A PE20161094A1 (en) 2009-10-01 2010-08-01 METHOD, KIT, PLASMID AND COMPOSITION TO INDUCE AN IMMUNE RESPONSE AGAINST DENGUE VIRUS BASED ON DNA VACCINES AND CHEMERIC VIRUSES

Country Status (10)

Country Link
US (1) US10357558B2 (en)
EP (1) EP2484376A4 (en)
CN (1) CN102711817B (en)
BR (1) BRPI0904020B8 (en)
CL (1) CL2012000783A1 (en)
CO (1) CO6541529A2 (en)
CU (1) CU24060B1 (en)
EC (1) ECSP12012131A (en)
PE (2) PE20121171A1 (en)
WO (1) WO2011038473A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6818548B2 (en) * 2013-03-15 2021-01-20 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Compositions and Methods for Dengue Virus Chimeric Constructs in Vaccines
AU2014281713A1 (en) 2013-06-21 2015-11-12 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
ITRM20130458A1 (en) 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And ANTI-DENGUE VIRUS GENETIC VACCINE BASED ON THE ECTODOMINS OF THE PROTEIN ENVELOPE
BR112017013270A2 (en) * 2014-12-22 2018-03-06 Merck Sharp & Dohme "dengue virus vaccine composition, methods for inducing a dengue immune response, reducing the likelihood of dengue infection, or preventing or alleviating dengue symptoms, and use of a dengue virus vaccine composition."
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
BR112021003962A2 (en) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. unit dose of dengue vaccine and its administration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (en) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz mutant and infectious yellow fever virus cdna, DNA construct, recombinant yellow fever virus and human vaccine against yellow fever infections.
US6881723B1 (en) * 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
NZ535690A (en) * 2002-02-26 2009-04-30 Maxygen Inc Novel flavivirus antigens
ZA200802176B (en) * 2005-08-10 2009-08-26 Acambis Inc Vaccination against dengue virus infection
BRPI0614265A2 (en) 2005-08-10 2011-03-22 Acambis Inc use of a yellow fever virus vaccine and a chimeric flavivirus vaccine and kit containing such vaccines
CU23586A1 (en) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS
EP2462930B1 (en) * 2006-11-09 2017-05-31 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
CA2708668C (en) * 2008-01-11 2019-03-05 Vgx Pharmaceuticals, Llc Vaccines against multiple subtypes of dengue virus

Also Published As

Publication number Publication date
CO6541529A2 (en) 2012-10-16
EP2484376A4 (en) 2014-01-22
ECSP12012131A (en) 2013-02-28
BRPI0904020A2 (en) 2011-06-14
WO2011038473A8 (en) 2012-07-19
CU24060B1 (en) 2014-12-26
US10357558B2 (en) 2019-07-23
BRPI0904020B1 (en) 2019-11-12
EP2484376A1 (en) 2012-08-08
CU20120057A7 (en) 2013-01-30
WO2011038473A1 (en) 2011-04-07
US20120251570A1 (en) 2012-10-04
CL2012000783A1 (en) 2013-03-22
BRPI0904020B8 (en) 2021-05-25
CN102711817B (en) 2016-10-26
CN102711817A (en) 2012-10-03
PE20161094A1 (en) 2016-10-22

Similar Documents

Publication Publication Date Title
PE20121171A1 (en) METHOD, KIT, PLASMID AND COMPOSITION TO INDUCE AN IMMUNE RESPONSE AGAINST DENGUE VIRUS BASED ON DNA VACCINES AND CHEMERIC VIRUSES
EA201201025A1 (en) NUCLEIC ACID MOLECULES OF INFLUENZA AND VACCINES PRODUCED FROM THEM
ES2662801T3 (en) Vaccines attenuated against Streptoccocus suis and their manufacturing and use procedures
BRPI0913012A2 (en) chimeric west nile / dengue virus
NO20090194L (en) Recombinant viral vaccine
EA033386B1 (en) RECOMBINANT IMMUNOGENE POLYPEPTIDES OF THE STEMPERE DOMAIN HEMAGGLUTININ VIRUS A AND DOMAIN USE
DK1976871T3 (en) Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for its use
JP2009544333A5 (en)
EA202092990A2 (en) NUCLEIC ACID MOLECULE CODING THE HEPATITIS B VIRUS CORE PROTEIN AND VACCINE CONTAINING THE INDICATED MOLECULE
CL2024001715A1 (en) Isolated antibody that binds to the dengue virus e protein; and use.
AR061484A1 (en) DNA SEQUENCES OF PROTEIN VECTORS AND USES OF AVIAR FLU HEMAGLUTININ
AR087020A1 (en) RELAXIN FUSION POLIPEPTIDES AND USES OF THE SAME
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
MX358725B (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same.
AR086078A1 (en) FUSION PROTEINS AND COMBINATION VACCINES
CL2012000447A1 (en) Composition or vaccine comprising a recombinant avian paramyxovirus 8 (apmv-8) viral vector; method of producing said vector; and use to prepare medicament useful for inducing an immune response.
BR112015005987A2 (en) vaccine, methods for inducing an immune response against an hbv antigen, for protecting a subject from hbv infection, for protecting the subject who was diagnosed with an hbv infection, for inducing an immune response against an hbv antigen, for protecting a individual from hbv infection, to protect an individual who was diagnosed with hbv infection, to protect an individual from hbv infection, to protect an individual who was diagnosed with hbv infection, to protect a subject from hbv infection, and to protect the subject who was diagnosed with an infection with hbv, nucleic acid molecule, and protein
MX383416B (en) NEW SWINE FLU VACCINE.
AR094725A1 (en) PARVOVIRUS 5A PORCINO, METHODS OF USE AND VACCINE
MX2017014417A (en) Dengue vaccines.
EA200601043A1 (en) PROMOTERS FOR EXPRESSION IN MODIFIED OVIPACAXI STRAIN VIRUS VIRUS
AR067439A1 (en) ANTIGENIC CHEMICAL VIRUSES OF ST. LOUIS / VIRUS DENGUE TYPE 4
CU23245A1 (en) CHEMICAL CODING CHAINS FOR INDUCTIVE PROTEINS OF VIRUS EFFECTS. PREPARED USING CHEMICAL PROTEINS
He et al. Putative suppressing effect of IgG Fc-conjugated haemagglutinin (HA) stalk of influenza virus H7N9 on the neutralizing immunogenicity of Fc-conjugated HA head: implication for rational design of HA-based influenza vaccines
Kulkarni et al. Construction of envelope domain III based recombinant tetravalent dengue vaccine

Legal Events

Date Code Title Description
FG Grant, registration